These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 35541919)

  • 1. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance.
    Zhang A; Miao K; Sun H; Deng CX
    Int J Biol Sci; 2022; 18(7):3019-3033. PubMed ID: 35541919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconciling environment-mediated metabolic heterogeneity with the oncogene-driven cancer paradigm in precision oncology.
    Vander Linden C; Corbet C
    Semin Cell Dev Biol; 2020 Feb; 98():202-210. PubMed ID: 31103464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies.
    El-Tanani M; Rabbani SA; Babiker R; Rangraze I; Kapre S; Palakurthi SS; Alnuqaydan AM; Aljabali AA; Rizzo M; El-Tanani Y; Tambuwala MM
    Cancer Lett; 2024 Jun; 591():216894. PubMed ID: 38626856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of cancer-associated fibroblasts: Opportunities for precision medicine.
    Kanzaki R; Pietras K
    Cancer Sci; 2020 Aug; 111(8):2708-2717. PubMed ID: 32573845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity.
    Mansouri S; Heylmann D; Stiewe T; Kracht M; Savai R
    Elife; 2022 Sep; 11():. PubMed ID: 36074553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor microenvironment and cancer therapy resistance.
    Sun Y
    Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?
    El-Deiry WS; Taylor B; Neal JW
    Am Soc Clin Oncol Educ Book; 2017; 37():e8-e15. PubMed ID: 28746017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision medicine: Ray of hope in overcoming cancer multidrug resistance.
    Musyuni P; Bai J; Sheikh A; Vasanthan KS; Jain GK; Abourehab MAS; Lather V; Aggarwal G; Kesharwani P; Pandita D
    Drug Resist Updat; 2022 Dec; 65():100889. PubMed ID: 36403342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial transcriptomics in cancer research and potential clinical impact: a narrative review.
    Cilento MA; Sweeney CJ; Butler LM
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):296. PubMed ID: 38850363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Resistance in Cancers: A Free Pass for Bullying.
    Li J; Li X; Guo Q
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cancer metabolism on therapy resistance - Clinical implications.
    Gonçalves AC; Richiardone E; Jorge J; Polónia B; Xavier CPR; Salaroglio IC; Riganti C; Vasconcelos MH; Corbet C; Sarmento-Ribeiro AB
    Drug Resist Updat; 2021 Dec; 59():100797. PubMed ID: 34955385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.
    Liu K; Cui JJ; Zhan Y; Ouyang QY; Lu QS; Yang DH; Li XP; Yin JY
    Mol Cancer; 2022 Apr; 21(1):98. PubMed ID: 35410257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy.
    Imodoye SO; Adedokun KA; Bello IO
    Histochem Cell Biol; 2024 Apr; 161(4):299-323. PubMed ID: 38189822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.
    Van den Bossche V; Zaryouh H; Vara-Messler M; Vignau J; Machiels JP; Wouters A; Schmitz S; Corbet C
    Drug Resist Updat; 2022 Jan; 60():100806. PubMed ID: 35121337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy guided precision medicine in solid tumors.
    Mehrotra S; Kupani M; Kaur J; Kaur J; Pandey RK
    Adv Protein Chem Struct Biol; 2024; 140():249-292. PubMed ID: 38762271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
    Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
    Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction.
    Jena BC; Mandal M
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188488. PubMed ID: 33271308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
    Dzobo K
    OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
    Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
    Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.